Marc Carrier on the WAVe Study: Weight-Adjusted Dalteparin is Safe & Effective in Large Cancer Patients with VTE
Marc Carrier, Professor at Ottawa Hospital Research Institute, shared on X:
“New in American Journal of Hematology – The WAVe Study
In patients >90 kg with cancer-associated VTE, weight-adjusted dalteparin (up to 33,000 IU/day) showed acceptable 30-Day bleeding (5.3%) and low recurrence (1.2%), supporting individualized dosing.”
Title: A Multicenter Prospective Cohort Study on the Use of Weight-Adjusted Dalteparin in Patients Over 90 kg With Acute Cancer-Associated Venous Thromboembolism—The WAVe Study
Authors: Tzu-Fei Wang, Erik Yeo, Peter L. Gross, Chantal Séguin, Cynthia Wu, Sudeep Shivakumar, Ranjeeta Mallick, Aurélien Delluc, Julien D’Astous, Miriam Kimpton, Guillaume Roberge, Deborah M. Siegal, Tobias Tritschler, Grégoire Le Gal, Marc Carrier
Read full article here.
Stay updated with Hemostasis Today.
-
Dec 16, 2025, 16:56Kathryn Mikkelsen on The Beat: Vasculearn Network’s Newsletter for Clot Survivors
-
Dec 16, 2025, 16:50Raul Santos on Sex-Specific Biology and Plasma Fructose Levels in Cardiovascular Risk
-
Dec 16, 2025, 16:34Mads Krogsgaard Thomsen on Novo Nordisk Haemophilia Foundation’s Support for Haemoglobinopathies
-
Dec 16, 2025, 16:22Leonardo Furtado Freitas Presents a Rare Hemorrhagic Hemangioblastoma Case
-
Dec 16, 2025, 16:14Nicolas Gendron on Sustainability in Anticoagulation and DOACs
-
Dec 16, 2025, 15:39Reza Shojaei: Every Expired Unit of Blood Tells a Story
-
Dec 16, 2025, 14:03Francesco Lo Monaco on Rethinking Blood Pressure: The Major Problem with How We Understand It
-
Dec 16, 2025, 14:03Marilena Vrana Urges EU Policymakers to “Keep Patients at the Centre” of Critical Medicines Act
-
Dec 16, 2025, 14:02Even Distribution of Protective Hemoglobin Prevents Sickle Cell Symptoms